Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: World J Urol. 2020 Jul 15;39(3):687–699. doi: 10.1007/s00345-020-03344-3

Figure 5:

Figure 5:

62-year-old man with metastatic castrate resistant prostate cancer, and PSA of 134ng/ml. 18F-DCFPYL imaging, including maximal intensity projection (A), and axial and sagittal fused PET/CT images (B1, B2, B3) demonstrate liver metastases (B1) and wide-spread osseous metastatic disease (A, B2, B3).